-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $98

Benzinga·05/07/2025 15:11:48
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $112 to $98.